Levodopa/Carbidopa/Entacapona Stada

Levodopa/Carbidopa/Entacapone, the active ingredient in Levodopa/Carbidopa/Entacapone Stada, is a Levodopa/Carbidopa/Entacapone combination presented as an oral tablet for oral use. It is prescribed to manage Parkinson's disease by replenishing central dopamine levels in affected patients through enhanced delivery of levodopa to the brain.

GNH USA supplies Levodopa/Carbidopa/Entacapone Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. All batches are manufactured under EU GMP guidelines to ensure consistency and safety.

Levodopa/Carbidopa/Entacapone is used in the management of Parkinson's disease and related motor complications.

- Parkinson's disease (early-stage): improves motor function, reduces rigidity and bradykinesia. - Parkinson's disease with motor fluctuations: extends the duration of levodopa effect and decreases OFF periods. - Advanced Parkinson's disease: helps control dyskinesia when used as part of combination therapy.

Levodopa/Carbidopa/Entacapone may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Dizziness: especially when standing quickly. - Headache: transient and often resolves with continued therapy. - Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects: - Hallucinations: visual or auditory disturbances requiring medical review. - Severe hypotension: marked drop in blood pressure leading to fainting. - Neuroleptic malignant syndrome: rare but life‑threatening reaction with fever and muscle rigidity. - Dyskinesia: involuntary movements that may become disabling.

When prescribing Levodopa/Carbidopa/Entacapone, clinicians should observe several precautionary measures to ensure patient safety.

- Dose adjustment: titrate according to clinical response and tolerability. - Renal impairment: monitor renal function and adjust dose if necessary. - Hepatic impairment: use with caution in patients with liver disease. - Cardiovascular disease: watch for orthostatic hypotension and arrhythmias. - Psychiatric history: monitor for hallucinations or worsening depression. - Store at ambient temperature: keep below 25°C, protect from moisture and light.

Levodopa/Carbidopa/Entacapone can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - MAO‑B inhibitors: risk of hypertensive crisis when combined. - Anticholinergics: may mask Parkinsonian symptoms and reduce therapeutic benefit. - Iron supplements: reduce levodopa absorption, diminishing clinical effect.

Moderate Interactions (Monitor Closely): - SSRIs: possible serotonin syndrome; monitor for symptoms. - Beta‑blockers: may increase dizziness and orthostatic hypotension.